SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• SAB Biotherapeutics (NASDAQ:SABS) has a consensus rating of "Moderate Buy" from six brokerages (1 sell, 4 buy, 1 strong buy) with an average 12‑month target of $10.00.
• Analyst views and price targets are mixed: Guggenheim and Chardan assigned buy ratings with $15 and $14 targets respectively, while HC Wainwright and UBS set $7 targets and Wall Street Zen cut its rating to sell.
• Recent fundamentals show a market cap of about $211M and the stock opened at $4.15; the company reported an EPS miss of ($0.46) vs. ($0.16) expected, analysts forecast ~-3.69 EPS for the year, and institutional ownership is roughly 7.82%.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) has received a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $10.00.

A number of analysts have issued reports on SABS shares. Wall Street Zen cut shares of SAB Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright lowered their price objective on SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday. Chardan Capital lifted their price target on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday. Guggenheim began coverage on shares of SAB Biotherapeutics in a report on Friday, December 19th. They set a "buy" rating and a $15.00 target price on the stock. Finally, UBS Group assumed coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a "buy" rating and a $7.00 price target for the company.

Institutional Trading of SAB Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics during the third quarter valued at about $30,000. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter worth about $32,000. State of Wyoming purchased a new stake in SAB Biotherapeutics during the 4th quarter valued at $34,000. Virtu Financial LLC bought a new stake in shares of SAB Biotherapeutics in the third quarter worth $40,000. Finally, State Street Corp purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter worth $49,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABS opened at $4.15 on Friday. The company has a market capitalization of $211.44 million, a price-to-earnings ratio of -1.79 and a beta of 0.59. The business has a 50-day moving average of $4.02 and a 200-day moving average of $3.36. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 10.50. SAB Biotherapeutics has a 1-year low of $1.00 and a 1-year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.30). On average, equities analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.